JPS6112621A - Cataplasma - Google Patents

Abstract

PURPOSE:A cataplasma obtained by incorporating a cataplasma base containing water with a surfactant having a specific HLB value and an active constituent insoluble or sparingly soluble in water. CONSTITUTION:A cataplasma, obtained by incorporating a hydrous cataplasma base, e.g. hydrous gel base crosslinkable with metallic ions (preferably nongelatin type base containing polyacrylic acid and polyacrylate and further sodium carboxymethyl cellulose and/or alkali metal alginate0 with 0.1-40wt% surfactant having 1-9 HLB value, e.g. sorbitan ester of a fatty acid, and 0.01-20wt% active constituent insoluble or sparingly soluble in water, e.g. indomethacin, and having high percutaneous absorption of the active constituent. The above-mentioned composition permits the stable compounding of the active constituent insoluble or sparingly soluble in water and high percutaneous absorption of the active constituent. KABURE, etc. is not easily caused in the skin, and the safety is excellent.

Description

DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a poultice agent, and more specifically, the present invention relates to a poultice agent, in which active ingredients that are insoluble or poorly soluble in water, such as anthranilic acid derivatives, indomethacin, and Nisder salicylates, are blended into a poultice base material containing water. In some cases, these active ingredients are well inhibited from precipitating as crystals or hydrolyzing in the base material,
The present invention relates to a poultice agent which can stably incorporate a water-insoluble or sparingly soluble active ingredient into a poultice base material containing water, and which can enhance the absorption of the active ingredient through rod skin.

Conventionally, it has been known that it is effective to use poultices using poultice base materials containing water, such as aqueous poultice base materials, for the treatment of bruises, sprains, lower back pain, stiff shoulders, muscle pain, inflammation of the skin, rheumatism, etc. Are known. That is, when transdermally absorbing active ingredients to treat bruises, etc., it is effective to hydrate the stratum corneum of the skin in order to promote the penetration of the active ingredients deep into the skin. However, when a poultice containing the above active ingredients is used in a poultice containing water, such as an aqueous poultice base, and is applied to the affected area, the moisture in the poultice material penetrates into the stratum corneum of the skin. The skin's stratum corneum is hydrated,
Moreover, this hydration state is maintained for a long time, so
The active ingredients in the pump base material are efficiently absorbed through the skin, promoting the healing of scars. Therefore, in this respect, poultices using a poultice base material containing water are superior therapeutic means compared to liquid preparations/softeners, which have problems such as volatilization of the solvent after application and adhesion to clothing.

As mentioned above, poultices using poultice base materials containing water are an excellent therapeutic means, and therefore, such poultices are effective against bruises, sprains, lower back pain, stiff shoulders, muscle pain, rheumatism, etc. It is an effective means to incorporate active ingredients such as anthranilic acid derivatives, indomethacin, and salicylic acid esters, which have anti-inflammatory and analgesic effects. However, anthranilic acid derivatives, indomethacin, and salicylic acid esters are water-insoluble or poorly water-soluble; however, when such water-insoluble or poorly water-insoluble active ingredients are blended into a poultice base containing water, Various problems arise.

In other words, when anthranilic acid derivatives such as mefenamic acid, flufenamic acid, and their derivatives are blended into a poultice base material containing water, dispersing the anthranilic acid derivative fine powder in the iron material may partially dissolve the anthranilic acid derivative. Even if anthranilic acid derivatives can be dissolved in a base material, most of the anthranilic acid derivatives exist in a solid state, so the excellent anti-inflammatory and analgesic effects of anthranilic acid derivatives cannot be fully exploited. In this case, it is conceivable to mix lower alcohols such as ethanol with the base material in order to dissolve the anthranilic acid derivative, but since the water in the base material and the lower alcohols easily mix, The Is form of anthranilic acid dissolved in the alcohol precipitates as crystals in the base material, and even with this method, the anti-inflammatory and analgesic effect of the anthranilic acid derivatives cannot be fully brought out. Furthermore, in order to incorporate into the base material an amount of an1-ranilic acid derivative that can be expected to have a pharmacological effect using this method, lower alcohols must be blended into the base material at a high concentration, which may be harmful to the skin. unfavorable in terms of safety.

Furthermore, when indomethacin is blended as an active ingredient, lower alcohols may also be blended into the base material for the purpose of dissolving indomethacin, but this also causes the same problems as the above-mentioned blending of anthranilic acid derivatives. .

Furthermore, when salicylic acid esters are blended into the poultice base material containing water, C salicylic acid esters may vary depending on storage temperature and storage period.
There is a problem in that the hydrolysis of TJ and r-sters is significantly accelerated and storage stability is poor. In this case, it is conceivable to suppress the hydrolysis of the salicylic acid esters as much as possible by adjusting the − of the base material, but a sufficient hydrolysis suppressing effect cannot be expected with this method.

In view of the above circumstances, the present inventors have discovered that an effective ingredient that is insoluble or sparingly soluble in water, such as anthranilic acid derivatives, indomethacin, and salicylic acid esters, is added to a pap filling material containing ice. As a result of various research into creating a poultice that suppresses ingredients from crystallizing or hydrolyzing, stably blends active ingredients, and effectively exerts its effects, we have developed an aqueous poultice. It has been found that the above object can be effectively achieved by incorporating a surfactant having an HLB value of 1 to 9 into a poultice base material containing water, such as a base material.

That is, the present inventors have found that when a surfactant with a strong lipophilicity and an HLB value of 1 to 9 and which is preferably liquid at room temperature or a liquid containing some solid content is blended into a poultice base material containing water,
This surfactant is a good solvent for anthranilic acid derivatives and indomethacin, and since this surfactant is not easily miscible with water, the anthranilic acid derivatives and indomethacin are stably blended into the base material in a dissolved state. Inconveniences such as the active ingredient precipitating as crystals are unlikely to occur, and it is! Even when thylic acid esters are blended, their hydrolysis is suppressed, and Salidil FFfT esters are stably blended, improving storage stability.
The present invention was based on this knowledge.

According to the present invention, for a poultice agent using a poultice base material containing water, which is ideal as a preparation for covering the skin as an application site,
Anthranilic acid derivatives, which were previously difficult to mix stably,
It can stably contain active ingredients that are insoluble or poorly soluble in water, such as indomethacin and salicylic acid esters, and therefore has a high transdermal absorption rate and can maximize its mulberry effect. be. Moreover, according to the present invention, active ingredients that cause 01 effects such as gastrointestinal disorders when administered internally can be efficiently administered transdermally directly to the affected area, which contributes to the safety of treatment. be.

The present invention will be explained in more detail below.

The poultice according to the present invention has HL in the poultice base material containing water.
A surfactant with a B value of 1 to 9 is blended, and this active ingredient is used when an active ingredient that is insoluble or sparingly soluble in water is blended into a six-tube base material.

precipitates as crystals or hydrolyzes in the base material.

It is possible to suppress such problems and to stably mix the ingredients.

In this case, the type of poultice base material containing water in the present invention is not limited, and both water-based and oil-based ones can be used, but in particular water-based poultice base materials using water-soluble polymer substances, However, metal- and ion-crosslinked hydrogel base materials are preferably used, which can more reliably enhance the transdermal absorption of the active ingredient. It is preferable to use a material containing 95% (weight%, same hereinafter).Also, as a base material, the state is 4 to 7.
It is preferable to use one.

Here, the composition of the aqueous poultice base material is not particularly limited, and any composition may be used. For example, polyacrylic acid, polyacrylate, polyvinyl alcohol, polyvinylpyrrolidone, polyvinylpyrrolidone/vinyl acetate copolymer, sodium carboxymethylcellulose, hydroxypropylcellulose, alginate, gelatin, pectin, polyethylene oxide, methyl vinyl ether/maleic anhydride copolymer φ coalescence, 1 gi or two or more types of water-soluble polymer substances such as carboxymethyl starch (compounding amount usually 1 to 15% of the entire base material. If it is less than 1%, sufficient viscosity as a coalescence paste cannot be obtained,
%, the viscosity may increase and workability may decrease. ), kaolin, bentonite, montmorillonite,
One or more types of inorganic powder such as titanium oxide, zinc oxide, aluminum hydroxide, silicic anhydride (e.g. Aerosil [F]) (formulation M usually 0 to 10%. - There is no particular restriction on the upper limit. ), propylene glycol, glycerin, sorbitol, polyethylene glycol, sodium pyrrolidone carboxylate, sodium lactate, etc., or a moisturizing agent of 28i or more (compounding amount is usually 0 to 20%) There is no particular upper limit on the upper limit, and it is determined depending on the balance with the water content.) and water in an appropriate ratio can be used.

In the present invention, a metal ion cross-linked hydrogel base material is preferably used as the aqueous poultice base material, but as the metal ion cross-linked hydrogel base material, polyacrylic acid and polyacrylic acid are preferred. A non-gelatin type substrate containing an acid salt and further containing sodium carboxymethylcellulose and/or alkali gold alginate WAm may be particularly preferably used. In other words, since the hydrogel base material with the above composition has strong adhesive strength, high water content, and excellent shape retention, when an active ingredient is blended with this hydrogel base material, the active ingredient is efficiently absorbed into the skin. In addition, the hydrogel base material having the above composition can be made into a base material having an arbitrary state by changing the blending ratio of polyacrylic acid and polyacrylate; however, in this case, polyacrylic The blending ratio (weight ratio) of acid and polyacrylate is preferably 1:9 to 8:2, and polyacrylic I! If the weight is less than 1710 of the weight of polyacrylic acid-polyacrylate, sufficient adhesion to the skin may not be obtained. 1 if it is more than 8/10 of the weight of salt
The paste may sag due to insufficient thickening.

° In this case, when the hydrogel base material consisting of the above components is metal-crosslinked with a polyvalent metal salt, the polyvalent metal salts include calcium chloride, magnesium chloride, aluminum chloride, potash bright bread, ammonium bright bread, iron bread, Soluble salts such as aluminum sulfate, ferric acid, magnesium sulfate, EDTA-calcium, EDTA-aluminum, EDTA-magnesium, stannous chloride, calcium hydroxide,
Hydroxide second ridge, aluminum hydroxide, calcium carbonate,
Magnesium carbonate, calcium phosphate, magnesium stearate, aluminum stearate, calcium citrate, barium sulfate, barium hydroxide, aluminum allantoinate, aluminum acetate, aluminum glycinal, stannous hydroxide, α-stannic acid, etc. One or more salts selected from soluble or poorly soluble salts, etc.;
It is possible to incorporate a salt, an organic salt, an organic base, etc., which has the ability to chelate or coordinate metal ions such as citric acid, tartaric acid, urea, and ammonia. In addition, in the present invention, an oil-based material may be used as the poultice base material, and in this case, a styrene-isoprene block polymer (A-B-
A type block polymer), natural rubber, synthetic rubber, acrylic resin, and other oil-soluble polymer substances can be blended in an amount of 1 to 80% of the total amount.

In the present invention, the above-mentioned pap base material has an HLB value of 1.
A surfactant having a number of 1 to 9 is blended. In this case, the type of surfactant with an HLB value of 1 to 9 is not limited,
Any of them can be used, such as those exemplified below: 181! Or two or more types can be used. Note that it is preferable to use a surfactant that is liquid at 20 to 40°C or a liquid containing some solid content.

Surfactants Comparison 1 Sorbitan monolaurate 8.6 Sorbitan monopalmitate 6.7 Sorbitan monostearate 4.7 Sorbitan sesquistearate 4.2 Sorbitan tristearate
2.1 Sorbitan monooleate NIKKOL'5o-104,3'NIKKO
L 5o-1OR5,0 Sorbitan sesquioleate NIKKQl-80-154,5 Sorbitan trioleate NIKKQl,, 80 -30
4.0-Sorbitan [neuisostearate 5.0 Sorbitan hiskiisostearate
4.5 Sorbitan Monotol Oil Fatty Acid 4.3 J Sorbitan Tritol Oil Fatty Acid 3,7 1 Sorbitan Tritol Oil Fatty Acid 1.7 Ester Glyceryl Seven Caprylate NIKKOL MGK 7,0 Glyceryl Mono A Leate 3.0 Glyceryl Mono Stearate 2.0 Glyceryl Monoisostearate 4.0'Po1! Glyceryl monooleate 5.0 Ethylene glycol monostearate 3.5 Diethylene glycol stearate 4
．． 5 polyethylene glycol 8.5 distearate polyethylene glycol dioleate-1 to 9.0 propylene glycol monolaurate NIKKOL PML-13,6 propylene glycol monolaurate 3.5 stearate propylene glycol 4.0 monostearate (self-emulsifying Type) POE (6) Sorbittetra 8.5 Oleate POE (1) Monostearate 2.0PO,E
(2) Monostearate 4.0POE (4) Monostearate 6.5POE (2) Monooleate 4.5POE (6) Monooleate
8.5POr(2,) lauryl L-thyl, 7
．． 01) OE (/1.2) lauryl, 1-thyl 8.
0POE (2>1!Tyl ether 8.0POE
IE<2)7 Ruylether 7.5POj(2
) alkyl1. - Full 9.0poe (2>nonylphenyl ether 4.5POE (5) Nonylphenyl ether 8.0POE (3) Octylphenyl 6.0"1-thyl POE (3) Castor oil 3.0POE
(10) Castor oil 6.5POE (5
) Hydrogenated castor oil 6.0POE (7,,5)
Hydrogenated castor oil 6.0POE (10) Hydrogenated castor oil 6.5 diPOE (2) Alkyl ether 6.5 phosphate diPOE (4) Alkyl ether °9.0 phosphate diPOE (6) Alkyl ether 9.0 Tri-POE phosphate <2> Alkyl ether 7.・0 phosphate tri-POE (4) Alkyl ether 7.0 phosphate POE (6) Sorbit beeswax 9.0 POE
Nonylphenyl formaldehyde condensate NrKKOL R-10053,0 POE nonylphenyl formaldehyde condensate NTKKOL R-10109',0 (Note: POE indicates 1 "polyoxyethylene" and the number in parentheses is the average of ethylene oxide. It is the number of moles added. Also, NrK
KOL indicates the product name of Nikko Chemicals. ) In the present invention, a surfactant having a 1-ILB value of 1 to 9 is blended in this way, but a surfactant having an HLB value of 9 is further blended.
There is no problem even if a surfactant exceeding 100% is added. However, in this case, it is preferable that the blended surfactant has an HLB value of 1 to 9 on average.

1-11 above. The blending amount of the surfactant with a B value of 1 to 9 is not necessarily limited, but the amount of the surfactant with a B value of 1 to 9 is not necessarily limited, but
It is preferably 40%, particularly 0.5 to 10%.

The poultice of the present invention uses a poultice base material containing water as described above)-
(A water-insoluble or sparingly soluble active ingredient is blended with a surfactant with an LB value of 1 to 9, and a water-insoluble or H-soluble active ingredient is used in combination with a surfactant with an H1B value of 1 to 9.) This allows these active ingredients to be stably blended into the poultice base material containing water.

Such active ingredients include mefenamic acid and its derivatives, flufenamic acid and its derivatives (for example, flufenamic acid salts, flufenamic acid alkyl esters such as butyl flufenamic acid, isobutyl flufenamic acid, etc.), derivatives of 77-ntranilic acid, Indomethacin, pricylic acid esters such as glycol salicylate and methyl salicylate, as well as diku-U funac sodium, aspirin, ibuprofen, sulindac, naproxen, piroxicam, thiaramide hydrochloride, fenbufen, J-menthol, peppermint oil, eucalyptus oil, and vitamin E1. Examples include diphen, vitamins, thymol, chili pepper extract, chili pepper, chili pepper tincture, kabsaicin, nonylic acid vanylamide, etc., and one or more of these active ingredients may be blended.

Although the amount of these active ingredients is not necessarily limited, it is usually 0.01 to 20%, preferably 0.3 to 5% of the entire poultice base material.

In addition, when blending an anthranilic acid derivative as an active ingredient, surfactants such as sorbitan fatty acid ester, POE castor oil, P, OE hardened castor oil, PO
When one or more selected from E alkyl ethers are used and indomethacin is blended, one type selected from P'OE alkyl ethers, POE alkylphenyl ethers, and POE alkyl ether phosphates is used as a surfactant. Or, when using two or more types and blending salicylic acid esters, surfactants such as sorbitan fatty acid ester, glycerin fatty acid sprue, polyethylene glycol fatty acid ester, POF alkyl[-thyl, POE alkyl fjnyl ether, PO
, E castor oil derivative, P OE hydrogenated castor oil derivative 1v! Alternatively, it is preferable to use two or more kinds.

Here, the method of blending the above-mentioned water-insoluble or sparingly soluble active ingredient into the group 4A is not limited, but a method of dissolving it in advance in a surfactant having an Ht-B value of 1 to 9 and blending it into the base material is possible. It can be suitably adopted.

Furthermore, in the present invention, in addition to the above-mentioned components, polymeric substances such as polybutene, latex, donyl acetate emulsion, acrylic resin emulsion, As a crosslinking gelling agent, appropriate components such as various polyvalent metal groups and organic crosslinking agents such as dialdehyde starch can be blended. Also,
Rolf maleic acid - Lamin, diphenhydramine hydrochloride, zturium salicylate, antipyrine, survirine, avapyrazone, miglenin, dibucaine hydrochloride, promethacin hydrochloride, fugaine phosphate, IJ dihydrocodine, ms ephedrine, isoproterenol hydrochloride, benzalcochloride Chlorhexidine gluconate, Sulfamethoxazole, Riotamiton, Allantoin,
Water-soluble active ingredients such as IFtdiamine can also be added, as well as desired ingredients that are commonly incorporated in the relaxing poultices.

The poultice of the present invention is prepared by thoroughly kneading the above-mentioned components to form a paste, which is coated on a support (backing) such as paper, woven fabric, non-woven fabric, or plastic film. This is obtained by subjecting □i to 7 Aicing.

Therefore, the poultice according to the present invention contains a surfactant having a 1-ILB value of 1 to 9 in the poultice base material containing water, so that anthranil 11211, indomethacin, salicylic acid esters, etc. By stably blending insoluble or sparingly soluble active ingredients into the skin, the amount of active ingredients absorbed through the skin is high. Furthermore, since a water-containing material is used as the bubble base material, skin irritation is likely to occur, and the product is highly safe for the skin.

Next, the present invention will be specifically explained by showing Examples and Comparative Examples.

[Examples 1-6. Comparative Example 1] An aqueous poultice base material having the composition shown in Table 1 was prepared according to a conventional method, spread and coated on a lint cloth to a uniform thickness, and the surface was further faced with a polyethylene film. Bag agents of Examples 1 to 6 and Comparative Example 1 were obtained, respectively. Here, the values of the water-based pap base materials were all within the range of 4.6 to 4.8.

Next, the following experiment 1.2 was conducted using the poultices of Examples 1 to 6 and Comparative Example 1.

Fruit $1 The anti-inflammatory effect of the poultices of Examples 1 to 6 and Comparative Example 1 was investigated by the following carrageenan foot edema suppression test.
.

Carrageenin foot edema suppression weight 140-160? Using a group of 10 male Wistar rats, the constant volume of the right hind paw of each rat was measured using a volume differential meter (VQOBa5ile).
After measuring with 1% carrageenin suspension (inflammatory agent)
0.1yf was injected subcutaneously into each leg. The poultice is pasted on the right 1 or 2 limbs 4 hours before the injection of the antiinflammatory agent, and after the injection, the fixed volume of the right hind limb is measured with the above meter, and the injection
The edema rate and the edema suppression rate of each poultice were determined from the difference in constant volume after fJ using the following formula. Please note that it was pasted during the test)
The rat's head and forelimbs were covered with a black cloth bag to prevent the rat from chewing or licking the whelk agent. In addition, a similar test was conducted for a control group in which no poultice was applied 4 hours before the t1 injection. Choto is shown in Table 2.

Edema rate (%) = (vt - Vn) / Vn xloo
VO: Constant volume before carrageenan injection Vt: Constant volume edema suppression rate 4 hours after carrageenin injection (
%) = (EC-E't) /Ec×100 EC: Average edema rate of control group Et: Average edema rate of poultice patch group Table 2: l: T-test 1% significant (vs.'@11￥ According to the results in Table 2, when the poultice of the example containing a surfactant with an Hl-B value of 1 to 9 was applied, the poultice of the comparative example containing no surfactant was applied. It was observed that the edema suppression rate was higher than when it was pasted. That is, in the poultice of the present invention, flufenamic acid was stably blended without precipitation as crystals, and therefore the anti-inflammatory effect of the blended flufenamic acid was sufficiently effectively exhibited. On the other hand, in the poultice of the comparative example, flufenamic acid precipitates and comes out as crystals.
Therefore, the anti-inflammatory effect of flufenamic acid was not effectively exhibited.

Support 1L The poultices of Examples 1 to 6 and Comparative Example 1 were applied to the upper arms of 20 healthy men, and their skin irritation was examined by a 48-hour closed patch test.

The results showed that all 20 subjects had no reaction to all poultices, indicating that the aqueous poultice base materials using the water-soluble polymer substances of Examples 1 to 6 and Comparative Example 1 had extremely low irritation.
I was caught.゛The adhesive force of the poultice described above was approximately 20 as determined by ball tack measurement at an inclination angle of 30 degrees, indicating that it had strong adhesive force and could be stably adhered to the skin.

[Examples 7 to 12, Comparative Example 2] A non-gelatin aqueous poultice base material having the composition shown in Table 3 was prepared according to a conventional method, and spread on a lint cloth to a uniform thickness.
Apply 1 fathom of poultice of polyethylene Comparative Example 2 on the surface. Here, in the preparation of the poultice in Example 1, 1z methacin was preliminarily adjusted to an HL B value of 1 to 1.
Surface activity of No. 9: Dissolved at the same time. In addition, the PH4, i IzN deviation of the aqueous poultice base material is also within the range of 4.6 to 4.8.

Next, the following Experiments 3 and 4 were conducted using the poultices of Examples 7 to 12 and Comparative Example 2.

Circle 11 The anti-inflammatory effects of the poultices of Examples 7 to 12 and Comparative Example 2 were investigated using the same carrageenan foot edema suppression test as in Experiment 1. The results are shown in Table 4.

Table 4 (Sweat) Based on the results in Table 2 (compared to the control group), surfactants with l-ILB values of 1 to 9 were blended. It was observed that when the poultice of the example was applied, the edema suppression rate was higher than when the poultice of the comparative example, which did not contain the above-mentioned surfactant, was applied. That is,
In the poultice of the present invention, there was no precipitation of indomethacin and it was stably blended, so the anti-inflammatory effect of the blended indomethacin was fully and effectively exhibited. On the other hand, in the poultice of Comparative Example 1, indomethacin was not stably blended and crystal precipitation occurred.
The anti-inflammatory effect of the blended indomethacin was not effectively exhibited.

Experiment 4 The poultices of Examples 7 to 12 and Comparative Example 2 were applied to the upper arms of 20 healthy men, and their skin irritation was examined by a 48-hour closed patch test. The results are shown in Table 5. The evaluation criteria are as follows. Also, the fifth
In the table, the positive rate is expressed as the percentage of positive subjects out of 20 subjects, with evaluation criteria of + (producing obvious erythema) or higher being considered positive.

Irritation evaluation criteria 1: No reaction ±: Slight erythema occurs on the skin +: Obvious erythema occurs → -l-': u Erythema and swelling or papules occur From the results in Table 5, Example 7 ~12. It was observed that the non-gelatin water-based ship base material using the water-soluble polymer material of Comparative Example 2 had extremely low irritation.

In addition, all of the above poultices were prepared at an inclination angle of 30 degrees (the adhesive force value measured by pull ball tack was about 20,
It has strong adhesive strength and sticks stably to the skin.

Examples 13 to 22 and Comparative Examples 3 and 4 The aqueous poultice base materials shown in Table 6.7 were prepared according to a conventional method, spread and coated on a lint cloth to a uniform thickness, and then The surface was faced with a polyethylene film to obtain poultices of Examples 13 to 22 and Comparative Example 3.4, respectively.

Next, the following Experiment 5 was conducted using the poultices of Examples 13 to 22 and Comparative Examples 3 and 4 above.

After milling one pair of each poultice, each of these was stored at 80° C. for 3 days, and the residual ratio of 4-noriderate glycol or methyl narichylate after storage compared to immediately after manufacture was determined. The results are shown in Tables 8 and 9.

Tables 8 and 9 show S'1 immediately after manufacture and S'1 after storage.

Table 8 Glycol salicylate Table 9 Methyl salicylate From the results in Table 8.9, the poultices of the examples containing surfactants with Hl and B values of 1 to 9 are the comparative examples that do not contain the above surfactants. It was observed that the residual rate of glycol salicylate and methyl salicylate after storage was higher than that of the padding agent. That is, in the poultice of the present invention, hydrolysis of glycol salicylate and methyl salicylate was well suppressed.

Furthermore, the relationship between the HLB value of the surfactant and the residual rate of glycol salicylate is shown in Figure 1, and the relationship between the HLB value of the surfactant and the residual rate of methyl salicylate is shown in Figure 2. From the results shown in the figure, it was found that the hydrolysis and hydrolysis of glycol salicylate and methyl nalicylate were particularly effectively suppressed by blending a surfactant with a HL8 value of 1 to 5.

[Brief explanation of the drawing]

@Figure 1 shows the HL B of the surfactant in the poultice of the present invention.
Figure 2 is a graph showing the relationship between one night stay and the residual rate of salicylate after storage of the poultice. This is a graph showing the relationship.

Claims (1)

[Scope of Claims] 1. A poultice agent comprising a water-containing poultice base material, a surfactant having an HLB value of 1 to 9, and a water-insoluble or sparingly soluble active ingredient. 2. The poultice according to claim 1, wherein the poultice base material is an aqueous poultice based on a water-soluble polymeric substance. 3. The poultice agent according to claim 2, wherein the poultice base material is a metal ion crosslinked hydrogel base material. 4. The pap according to claim 3, wherein the metal ion crosslinked hydrogel base material contains polyacrylic acid and polyacrylate, and further contains sodium carboxymethylcellulose and/or alkali metal alginate. agent. 5. The poultice according to claim 4, wherein the blending ratio of polyacrylic acid and polyacrylate is 8:2 to 1:9 by weight. 6. The poultice according to any one of claims 1 to 5, wherein the surfactant having an HLB value of 1 to 9 is a liquid or a liquid containing some solid content at 20 to 40°C. 7. The blending amount of surfactant is 0.1 to 4 of the entire pap base material.
The poultice according to any one of claims 1 to 6, which contains 0% by weight. 8. The poultice according to any one of claims 1 to 7, which contains an anthranilic acid derivative as an active ingredient. 9. The poultice according to claim 8, wherein the anthranilic acid derivative is mefenamic acid, flufenamic acid, or a derivative thereof. 10. The poultice agent according to claim 8 or 9, wherein the amount of the anthranilic acid derivative is 0.01 to 20% by weight of the entire poultice base material. 11. Claims 8 to 10 in which one or more surfactants selected from sorbitan fatty acid ester, polyoxyethylene castor oil, polyoxyethylene hydrogenated castor oil, and polyoxyethylene alkyl phenyl ether are used. The poultice according to any one of Item 10. 12. The poultice according to any one of claims 1 to 7, which contains indomethacin as an active ingredient. 13. The amount of indomethacin in the entire pap base material is 0.
13. The poultice according to claim 12, wherein the amount is 01 to 20% by weight. 14. Claims 12 or 13 in which one or more selected from polyoxyethylene alkyl ether, polyoxyethylene alkyl phenyl ether, and polyoxyethylene alkyl ether phosphate are used as surfactants. Poultice as described. 15. The poultice according to any one of claims 1 to 7, which contains a salicylic acid ester as an active ingredient. 16. The poultice according to claim 15, wherein the salicylic acid ester is glycol salicylate or methyl salicylate. 17. The poultice according to claim 15 or 16, wherein the content of the salicylic acid ester is 0.01 to 20% by weight of the entire poultice base material.